This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Low, D. E.
Right arrow Articles by Bast, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Low, D. E.
Right arrow Articles by Bast, D. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2002, p. 1119-1121, Vol. 46, No. 4
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.4.1119-1121.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Activity of BMS-284756, a Novel Des-Fluoro(6) Quinolone, against Staphylococcus aureus, Including Contributions of Mutations to Quinolone Resistance

D. E. Low,1,2* M. Muller,3 C. L. Duncan,1 B. M. Willey,1 J. C. de Azavedo,1,2 A. McGeer,1,2 B. N. Kreiswirth,4 S. Pong-Porter,1 and D. J. Bast1,2

Department of Microbiology, Toronto Medical Laboratories and Mount Sinai Hospital,1 Department of Laboratory Medicine and Pathobiology,2 Department of Medicine, University of Toronto, Toronto, Ontario, Canada ,3 Public Health Research Institute, New York, New York4

Received 24 September 2001/ Returned for modification 30 November 2001/ Accepted 8 January 2002

The in vitro activity of BMS-284756 against 602 Staphylococcus aureus isolates, including 152 that were both methicillin and ciprofloxacin resistant (MIC >=4 µg/ml), was determined. For ciprofloxacin-susceptible and nonsusceptible isolates, the MICs at which 50% of organisms were inhibited were 0.015 and 2 µg/ml and the MICs at which 90% of organisms were inhibited were 0.03 and 4 µg/ml, respectively.

* Corresponding author. Mailing address: Department of Microbiology, Rm. 1487, Mount Sinai Hospital, 600 University Ave., Toronto, Ontario, Canada, M5G 1X5. Phone: (416) 586-4435. Fax: (416) 586-8746. E-mail: dlow{at}mtsinai.on.ca.

Antimicrobial Agents and Chemotherapy, April 2002, p. 1119-1121, Vol. 46, No. 4
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.4.1119-1121.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Cheng, J., Thanassi, J. A., Thoma, C. L., Bradbury, B. J., Deshpande, M., Pucci, M. J. (2007). Dual Targeting of DNA Gyrase and Topoisomerase IV: Target Interactions of Heteroaryl Isothiazolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 51: 2445-2453 [Abstract] [Full Text]  
  • Pucci, M. J., Cheng, J., Podos, S. D., Thoma, C. L., Thanassi, J. A., Buechter, D. D., Mushtaq, G., Vigliotti, G. A. Jr., Bradbury, B. J., Deshpande, M. (2007). In Vitro and In Vivo Antibacterial Activities of Heteroaryl Isothiazolones against Resistant Gram-Positive Pathogens. Antimicrob. Agents Chemother. 51: 1259-1267 [Abstract] [Full Text]  
  • Bhagwat, S. S., Mundkur, L. A., Gupte, S. V., Patel, M. V., Khorakiwala, H. F. (2006). The Anti-Methicillin-Resistant Staphylococcus aureus Quinolone WCK 771 Has Potent Activity against Sequentially Selected Mutants, Has a Narrow Mutant Selection Window against Quinolone-Resistant Staphylococcus aureus, and Preferentially Targets DNA Gyrase . Antimicrob. Agents Chemother. 50: 3568-3579 [Abstract] [Full Text]  
  • Campion, J. J., Chung, P., McNamara, P. J., Titlow, W. B., Evans, M. E. (2005). Pharmacodynamic Modeling of the Evolution of Levofloxacin Resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 2189-2199 [Abstract] [Full Text]  
  • Hsueh, P.-R., Teng, L.-J., Chen, W.-H., Pan, H.-J., Chen, M.-L., Chang, S.-C., Luh, K.-T., Lin, F.-Y. (2004). Increasing Prevalence of Methicillin-Resistant Staphylococcus aureus Causing Nosocomial Infections at a University Hospital in Taiwan from 1986 to 2001. Antimicrob. Agents Chemother. 48: 1361-1364 [Abstract] [Full Text]  
  • Zhao, X., Eisner, W., Perl-Rosenthal, N., Kreiswirth, B., Drlica, K. (2003). Mutant Prevention Concentration of Garenoxacin (BMS-284756) for Ciprofloxacin-Susceptible or -Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 1023-1027 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»